Latest

Pulmonary Arterial Hypertension: Using Biomarkers to Assess Treatment Response

Pulmonary Arterial Hypertension: Using Biomarkers to Assess Treatment Response

Using biomarkers in pulmonary arterial hypertension may be a less invasive strategy for assessing response to treatment.

Thoracic and Pulmonary Conditions Associated With Connective Tissue Disease

Thoracic and Pulmonary Conditions Associated With Connective Tissue Disease

Pulmonary and thoracic symptoms often coincide with initial presentation of connective tissue disease.

Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: Definitions and Treatments

Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: Definitions and Treatments

Pulmonary arterial hypertension is becoming a major cause of death in patients with systemic sclerosis.

Idiopathic PAH vs Scleroderma-Associated PAH: Pulmonary Function and Hemodynamic Differences

Idiopathic PAH vs Scleroderma-Associated PAH: Pulmonary Function and Hemodynamic Differences

Results show statistically significant differences between SSc-PAH groups and iPAH groups for variables including age, sex, FVC capacity, total lung capacity, and FEV1, among others.

Impaired Cerebral Pressure-Flow Relationship in PAH

Impaired Cerebral Pressure-Flow Relationship in PAH

Patients with pulmonary arterial hypertension have reduced cerebrovascular reactivity to CO2.

Pulmonary Arterial Hypertension: Mechanisms of Exercise Intolerance

Pulmonary Arterial Hypertension: Mechanisms of Exercise Intolerance

Respiratory muscle dysfunction, iron deficiency, and skeletal muscle dysfunction have been implicated as mechanisms for exercise intolerance in pulmonary arterial hypertension.

Redesigned Inhalation Device for PAH Approved by FDA

Redesigned Inhalation Device for PAH Approved by FDA

The new device features a more ergonomic design with a single-button operation, an intuitive user interface to adjust breath counts, a rechargeable battery, and a display that guides patients through the inhalation process.

Phenotypes Associated With EIF2AK4 Mutations in PAH

Phenotypes Associated With EIF2AK4 Mutations in PAH

The frequency of eukaryotic translation initiation factor 2 alpha kinase 4 gene (EIF2AK4) mutations in patients with pulmonary arterial hypertension was investigated.

Pulmonary HTN Linked to Increased Mortality During Cardiac Catheterization

Pulmonary HTN Linked to Increased Mortality During Cardiac Catheterization

Borderline PH was linked to increased mortality after adjustment for 34 variables.

Pulmonary Edema After Prostacyclin Therapy for PAH Associated With Worse Outcomes

Pulmonary Edema After Prostacyclin Therapy for PAH Associated With Worse Outcomes

Patients who develop pulmonary edema after starting prostacyclin for pulmonary arterial hypertension have a greater risk for mortality.

PAH-Associated Congenital Heart Disease Outcomes Predicted by Pulmonary Artery Compliance

PAH-Associated Congenital Heart Disease Outcomes Predicted by Pulmonary Artery Compliance

Pulmonary vascular compliance may independently predict survival and prognosis in patients with pulmonary arterial hypertension associated with congenital heart disease.

Pulmonary Arterial Compliance Improved With Riociguat vs PDE5 Inhibitors

Pulmonary Arterial Compliance Improved With Riociguat vs PDE5 Inhibitors

Patients with pulmonary arterial hypertension experienced better improvements in pulmonary arterial compliance with riociguat compared with phosphodiesterase type 5 inhibitors.

Bronchoalveolar Lavage in Idiopathic Pulmonary Fibrosis Diagnosis: Point/Counterpoint

Bronchoalveolar Lavage in Idiopathic Pulmonary Fibrosis Diagnosis: Point/Counterpoint

Lung disease experts Athol Wells, MD, and Joshua Mooney, MD, MS, debate the diagnostic value of bronchoalveolar lavage in idiopathic pulmonary fibrosis.

Extent of Right Ventricular Epicardial Vascularization in Pulmonary Arterial Hypertension

Extent of Right Ventricular Epicardial Vascularization in Pulmonary Arterial Hypertension

Right ventricular epicardial vasculature is more extensive in patients with pulmonary arterial hypertension compared with individuals without disease.

No Associations Exist Between 6MWD and VO2peak in Pulmonary Arterial Hypertension

No Associations Exist Between 6MWD and VO2peak in Pulmonary Arterial Hypertension

Results indicate that further study of the relationship between the 6-minute walk distance test and functional capacity in PAH is necessary.

Association Between Pulmonary Hypertension and Hereditary Hemorrhagic Telangiectasia

Association Between Pulmonary Hypertension and Hereditary Hemorrhagic Telangiectasia

A study sought to describe the occurrence of different types of pulmonary hypertension in hereditary hemorrhagic telangiectasia.

Examining Anxiety, Depression Rates in CTEPH, PAH

Examining Anxiety, Depression Rates in CTEPH, PAH

Depression, anxiety, and reduced healthcare-related quality of life are common in patients with either pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.

Clinical Case: Patient With COPD and Worsening Dyspnea on Exertion

Clinical Case: Patient With COPD and Worsening Dyspnea on Exertion

A 65-year-old man with COPD presents with worsening exertional dyspnea.

Characteristics and Outcomes of Methamphetamine-Associated Pulmonary Arterial Hypertension

Characteristics and Outcomes of Methamphetamine-Associated Pulmonary Arterial Hypertension

Methamphetamine-associated pulmonary arterial hypertension has a higher risk for clinical worsening compared with idiopathic pulmonary arterial hypertension.

Pulmonary Veno-Occlusive Disease Affects Survival in PAH/Systemic Sclerosis

Pulmonary Veno-Occlusive Disease Affects Survival in PAH/Systemic Sclerosis

Having at least 2 features of pulmonary veno-occlusive disease demonstrated a trend toward worse survival in patients with pulmonary arterial hypertension and systemic sclerosis.

Sign Up for Free e-newsletters